NCT06229353

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 34 (actual)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate an ED-based HPV vaccination protocol and program for ED patients aged 18-26 (for whom catch-up HPV vaccination is routinely recommended by the CDC) and separately for patients aged 27-45 (for whom it may be recommended under shared decision making, SDM).

Conditions

• Human Papilloma Virus

Interventions

Type	Name	Description
BIOLOGICAL	Gardasil 9	Prevent HPV-associated diseases and cancers

Timeline

• Start date: 2024-08-08
• Primary completion: 2025-07-30
• Completion: 2025-07-30
• First posted: 2024-01-29
• Last updated: 2025-09-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study